Oskouian B, Lee J, Asgharzadeh S, Khan R, Zhang M, Weisbrod J
Oncogene. 2024; 43(16):1203-1213.
PMID: 38413795
PMC: 11014797.
DOI: 10.1038/s41388-024-02980-y.
Lam F, Kong Y, Huang Q, Vu Han T, Maffa A, Kasper E
Nat Commun. 2020; 11(1):4083.
PMID: 32796829
PMC: 7428008.
DOI: 10.1038/s41467-020-17503-y.
Ornell K, Taylor J, Zeki J, Ikegaki N, Shimada H, Coburn J
Cancer Med. 2020; 9(8):2891-2903.
PMID: 32096344
PMC: 7163090.
DOI: 10.1002/cam4.2936.
Huang X, Zhao J, Zhu J, Chen S, Fu W, Tian X
J Clin Lab Anal. 2019; 33(9):e22988.
PMID: 31343784
PMC: 7938399.
DOI: 10.1002/jcla.22988.
Taylor J, Zeki J, Ornell K, Coburn J, Shimada H, Ikegaki N
J Pediatr Surg. 2019; 54(6):1192-1197.
PMID: 30879743
PMC: 6545249.
DOI: 10.1016/j.jpedsurg.2019.02.028.
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.
Niemas-Teshiba R, Matsuno R, Wang L, Tang X, Chiu B, Zeki J
Oncotarget. 2018; 9(5):6416-6432.
PMID: 29464082
PMC: 5814222.
DOI: 10.18632/oncotarget.23740.
The MYCN Protein in Health and Disease.
Ruiz-Perez M, Henley A, Arsenian-Henriksson M
Genes (Basel). 2017; 8(4).
PMID: 28358317
PMC: 5406860.
DOI: 10.3390/genes8040113.
A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.
Ross R, Walton J, Han D, Guo H, Cheung N
Stem Cell Res. 2015; 15(2):419-26.
PMID: 26342562
PMC: 4601571.
DOI: 10.1016/j.scr.2015.08.008.
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
Wang L, Teshiba R, Ikegaki N, Tang X, Naranjo A, London W
Br J Cancer. 2015; 113(1):57-63.
PMID: 26035700
PMC: 4647535.
DOI: 10.1038/bjc.2015.188.
MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity.
Samaraweera L, Grandinetti K, Huang R, Spengler B, Ross R
BMC Cancer. 2014; 14:309.
PMID: 24885481
PMC: 4038381.
DOI: 10.1186/1471-2407-14-309.
Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
Wang S, Hsiao R, Limpar M, Lomahan S, Tran T, Maloney N
Int J Mol Med. 2013; 33(1):35-42.
PMID: 24190252
PMC: 3868499.
DOI: 10.3892/ijmm.2013.1545.
S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.
Ikegaki N, Hicks S, Regan P, Jacobs J, Jumbo A, Leonhardt P
Int J Oncol. 2013; 44(1):35-43.
PMID: 24173829
PMC: 3867363.
DOI: 10.3892/ijo.2013.2148.
Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression.
Carter R, Mullassery D, See V, Theocharatos S, Pizer B, Losty P
Oncogenesis. 2013; 1:e24.
PMID: 23552815
PMC: 3503288.
DOI: 10.1038/oncsis.2012.24.
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.
Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B
Proc Natl Acad Sci U S A. 2011; 109(4):E187-96.
PMID: 22190494
PMC: 3268300.
DOI: 10.1073/pnas.1105304109.
Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan P, Jacobs J, Wang G, Torres J, Edo R, Friedmann J
Int J Oncol. 2010; 38(1):105-12.
PMID: 21109931
PMC: 3212671.
Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J, Regan P, Edo R, Leonhardt P, Jeng E, Rappaport E
Int J Oncol. 2010; 37(4):983-91.
PMID: 20811720
PMC: 3212990.
DOI: 10.3892/ijo_00000749.
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.
Choi S, Wright J, Gerber S, Cole M
Genes Dev. 2010; 24(12):1236-41.
PMID: 20551172
PMC: 2885659.
DOI: 10.1101/gad.1920310.
MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
Alam G, Cui H, Shi H, Yang L, Ding J, Mao L
Am J Pathol. 2009; 175(2):856-66.
PMID: 19608868
PMC: 2716980.
DOI: 10.2353/ajpath.2009.090019.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Walton J, Kattan D, Thomas S, Spengler B, Guo H, Biedler J
Neoplasia. 2005; 6(6):838-45.
PMID: 15720811
PMC: 1531688.
DOI: 10.1593/neo.04310.
The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc.
Li J, Kretzner L
Mol Cell Biochem. 2003; 250(1-2):91-105.
PMID: 12962147
DOI: 10.1023/a:1024918328162.